Review of cisplatin and oxaliplatin in current immunogenic and monoclonal antibodies perspective

Oncology Reviews

Volumn 8, Issue 2, 2014, Pages

  Mehmood, Rao Khalid ^a  

^a BETSI CADWALADR UNIVERSITY HEALTH BOARD   (United Kingdom)

Author keywords

1,2 diaminocyclohexane (DACH); Cisplatin; DNA adducts; Mechanisms of action; Monoclonal antibodies; Oxaliplatin

Indexed keywords

CISPLATIN; HIGH MOBILITY GROUP B1 PROTEIN; MONOCLONAL ANTIBODY; OXALIPLATIN;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; DRUG EFFICACY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; REVIEW;

EID: 84907260718     PISSN: 19705557     EISSN: 19705565     Source Type: Journal    
DOI: 10.4081/oncol.2014.256     Document Type: Review

References (105)

1. Loehrer PJ, Einhorn LH. Drugs five years later. Cisplatin. Ann Intern Med 1984; 100(5): 704-13
2. Ozols RF. Ovarian cancer, Part II: Treatment. Curr Probl Cancer 1992; 16(2): 61-126
3. Ozols R.F and Williams S. Testicular cancer. Curr Probl Cancer 1989; 13: 285-335
4. Kavanagh J, Tresukosol D, Edwards C, et al. Carboplatin reintroduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 1995; 13: 1584-88
5. Misset J L, Bleiberg H, Sutherland W, et al. Oxaliplatin clinical activity: a review. Cri Rev Onc Haem 2000; 35(2): 75-93
6. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem. Pharmacol 1996; 52: 1855-65
7. Ji JH, Park SH, Lee J, et al. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis. Cancer Chemother Pharmacol 2013; 72(1): 223-30
8. Hurwitz HI, Tebbutt NC, Kabbinavar F, et al. Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials. Oncologist 2013; 18(9): 1004-12
9. Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Onc 2011; 18(1): 18-25
10. Jin F, Ji H, Jia C, et al. Synergistic Antitumor Effects of Endostar in Combination with Oxaliplatin via Inhibition of HIF and CXCR4 in the Colorectal Cell Line SW1116. PLoS One 2012; 7(10)
11. Faivre S, Djelloul S, Raymond E. New Paradigms in Anticancer Therapy: Targeting Multiple Signaling Pathways with Kinase Inhibitors. Semin Oncol 2006; 33: 407-20
12. Cisplatin-FDA prescribing information, side effects and uses. http://www.drugs.com/pro/cisplatin.htlm & http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/018057s079lbl.pdf 23/05/2014
13. Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 2001; 59(4): 657-63
14. Fuertes MA, Alonso C, Perez JM. Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance. Chem rev 2002; 103(3): 645-62
15. Yang XL, Wang AH. Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol ther 1999; 83(3): 181-215
16. Payet D, Gaucheron F, Sip M, Leng M. Instability of the monofunctional adducts in cis-[Pt(NH3)2(N7-N-methyl-2-diazapyrenium)Cl](2+)-modified DNA: rates of crosslinking reactions in cis-platinum-modified DNA, Nucleic Acids Res 1993; 21(25): 5846-51
17. Balconi G, Pang Y, Broggini M et al. Cis dichlorodiammine platinum induced DNA interstrand cross-links in primary cultures of human ovarian cancer. Br J Cancer 1991; 64(2): 288-92
18. Auge P, Kozelka J. Transformations and recognition of platinum-DNA adducts: recent developments. Transition Met Chem 1997; 22: 91-6
19. Eastman A, Barry MA. Interaction of trans-diamminedichloroplatinum(II) with DNA: formation of monofunctional adducts and their reaction with glutathione. Biochemistry 1987: 26(12), 3303-7
20. Szymkowski DE, Yarema K, Essigmann JM et al. An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts. Proc Natl Acad Sci USA 1992; 89(22): 10772-6
21. Mu D, Shu DS, Sancar A. Reaction mechanism of human DNA repair excision nuclease. J Biol Chem 1996; 271: 8285-94
22. excision nuclease. J Biol Chem 1996; 271: 8285-94
23. Pil PM, Lippard SJ. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science 1992; 256(5054): 234-7
24. Graf N, Lippard SJ. Redox activation of metal-based prodrugs as a strategy for drug delivery. Adv Drug Deliv Rev 2012; 64(11): 993-1004
25. Jamieson ER, Lippard SJ. Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem Rev 1999; 99(9): 2467-98
26. Todd RC, Lovejoy KS, Lippard SJ. Understanding the Effect of Carbonate Ion on Cisplatin Binding to DNA. J Am Chem Soc 2007; 129(20): 6370-6371.
27. Perez RP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 1998; 34(10): 1535-42
28. Miller SE. The Hydrolysis Products of cis-Diamine-dichloroplatinum(II). 4. The Anation Kinetics of cis-Pt(X)(NH3)2(OH2)+ (X = Cl, OH) with glycine, monohydrogen malonate and chloride. Inorg Chim Acta 1991; 187: 125-132
29. Kweekel DM, Gelderblom H, Guchelaar HJ. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualise therapy. Cancer Treatment Rev 2005; 31(2): 90-105
30. National cancer institute www.cancer.gov/oxaliplatin [14/05/2014]
31. Eloxatin. Summary of Product Characteristics Sanofi Winthrop Ltd. September 1999
32. Faivre S, Chan D, Salinas R, et al. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 2003; 66: 225-37
33. Woynarowski JM, Faivre S, Herzig MC, et al. Oxaliplatin induced damage of cellular DNA. Mol Pharmacol 2000; 58: 920-7
34. Raymond E, Faivre S, Chaney S, et al. Cellular and Molecular Pharmacology of Oxaliplatin, Mol Cancer Ther 2002; 1: 227-35
35. Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol 2011; 18(1): 18-25
36. Lu Y, Luo Z, Bregman DB. RNA polymerase II large subunit is cleaved by caspases during DNA damage-induced apoptosis. Biochem Biophys Res Comm 2002; 296: 954-61
37. Ang WH, Myint M, Lippard SJ. Transcription Inhibition by Platinum DNA Cross-Links in Live Mammalian Cells. J Am Chem Soc 2010; 132(21): 7429-35
38. Todd RC, Lippard SJ. Inhibition of transcription by platinum antitumor compounds. Metallomics 2009; 1: 280-91.
39. Svejstrup JQ. Mechanisms of transcription-coupled DNA repair. Nat Rev Mol Cell Biol 2002; 3(1): 21-9.
40. Nat Rev Mol Cell Biol 2002; 3(1): 21-9.
41. Bulmer JT, Zacal NJ, Rainbow AJ. Human cells deficient in transcription-coupled repair show prolonged activation of the Jun N-terminal kinase and increased sensitivity following cisplatin treatment. Cancer Chemother Pharmacol 2005; 56(2): 189-98
42. Jung Y, Lippard SJ. RNA polymerase II blockage by cisplatin-damaged DNA. Stability and polyubiquitylation of stalled polymerase. J Biol Chem 2006; 281: 1361-70
43. Hoffmann JS, Pillaire MJ, Lesca C, et al. Fork like support bypass replication of lesions that block DNA synthesis on single-stranded templates. Proc Natl Acad Sci USA 1996; 93: 13766-9
44. Wei M, Cohen SM, Silverman AP, Lippard SJ. Effects of Spectator Ligands on the Specific Recognition of Intrastrand Platinum-DNA Cross-links by High Mobility Group Box and TATA-binding Proteins. J Biol Chem 2001; 276(42): 38774-80
45. Cline SD. Mitochondrial DNA Damage and its Consequences for Mitochondrial Gene Expression. Biochim Biophys Acta 2012; 1819(9-10): 979-991
46. Suo Z, Lippard SJ, Johnson K A. Single d(GpG)/cis-diammineplatinum(II) adductinduced inhibition of DNA polymerization. Biochem 1999; 38: 715-26
47. Köberle B, Masters JR, Hartley JA, Wood RD. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 1999; 9: 273-6
48. Arnould S, Hennebelle I, Canal P, et al. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J of Cancer 2003; 39 (1): 112-9
49. Shirota Y, Stoehlmacher J Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19: 4298-304
50. Han JJ, Baek SK, Lee JJ, et al. Combination of TRAP1 and ERCC1 Expression Predicts Clinical Outcomes in Metastatic Colorectal Cancer Treated with Oxaliplatin/5-Fluorouracil. Cancer Res Treat 2014; 46(1): 55-64
51. Dempke W, Voigt W, Grothey A, et al. Cisplatin resistance and oncogenes-a review. Anticancer Drugs 2000; 11(4): 225-36
52. Hartwig A, Blessing H, Schwerdtle T, Walter I. Modulation of DNA repair processes by arsenic and selenium compounds. Toxicology 2003; 193: 161-9
53. Di Francesco AM, Ruggiero A, Riccardi R. Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell Mol Life Sci 2002; 59: 1914-27
54. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30
55. Lange SS, Takata K, Wood RD. DNA polymerases and cancer. Nat Rev Cancer 2011; 11(2): 96-110
56. Yamada M, O'Regan E, Brown R, Karran P. Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. Nucleic acids Res 1997; 25(3): 491-6
57. Katja C, Zimmermann CB, Green DR. The machinery of programmed cell death. Pharm Thera 2001; 92: 57-70
58. Lucas MF, Cabeza de Vaca I, Takahashi R, et al. Atomic Level Rendering of DNA Drug Encounter. Biophys J 2014; 106: 421-9
59. Kline CL, El-Deiry WS. Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action. Pharmaceuticals (Basel) 2013; 6(8): 988-1038
60. Moll UM, Zaika A. Nuclear and mitochondrial apoptotic pathways of p53 FEBS Lett 2001; 493: 65-9
61. Qin LF, Ng IO. Induction of apoptosis by cisplatin and its effect on cell cycle-related proteins and cell cycle changes in hepatoma cells. Cancer Lett 2002; 175: 27-38
62. Arner ES, Nakamura H, Sasada T et al. Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cisdiamminedichloroplatinum(II) and its major metabolite, the glutathione-platinum complex. Free Radic Biol Med 2001; 31: 1170-8
63. Woynarowska BA, Woynarowski JM. Preferential targeting of apoptosis in tumor Versus normal cells. Biochimica et Biophysica Acta (BBA) 2002; 1587: 309-17
64. Shiragami R, Murata S, Kosugi C et al. Enhanced antitumor activity of cerulenin combined with oxaliplatin in human colon cancer cells. Int J Oncol 2013; 43(2): 431-8
65. Stordal B, Davey M. Understanding cisplatin resistance using cellular models. IUBMB Life 2007; 59(11): 696-9
66. Vousden AK. Activation of the p53 tumor suppressor protein. Biochimica et Biophysica Acta (BBA) 2002; 1602: 47-59
67. Donahue RJ, Razmara M, Hoek JB, Knudsen TB. Direct influence of the p53 tumor suppressor on mitochondrial biogenesis and function. FASEB J 200; 15: 635-644
68. Tesniere A, Schlemmer F, Boige V, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29: 482-91
69. Donahue RJ, Razmara M, Hoek JB, Knudsen TB. Direct influence of the p53 tumor suppressor on mitochondrial biogenesis and function. FASEB J 2001; 15: 635-44
70. Chao MP, Jaiswal S, Weissmann-Tsukamoto R, et al. Calreticulin is the dominant prophagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2010; 2(63)
71. Tesniere A, Apetoh L, Ghiringhelli F, et al. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 2008; 20(5): 504-11
72. Herzig MC, Liang H, Woynarowski JM. Irofulven induces apoptosis in breast cancer cells regardless of caspase-3 status. Breast Cancer Res Treat 2002; 71: 133-143
73. Peng RQ, Chen RB, Ding Y, et al. Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer. World J Gastroenterology 2010; 16(19): 2428-34
74. Rock FL, Hardiman G, Timans JC, et al. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA 1998; 95 (2): 588-93.
75. http://www.science.gov/topicpages/d/damage+repair+pathway.html 29/04/2014
76. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17: 409-422
77. Chen W, Xiao Y, Liu X, et al. Overcoming cisplatin resistance in chemotherapy by biomineralization. Chem Commun 2013; 49: 4932-4
78. Hector S, Bolanowska-Higdon W, Zdanowicz J, et al. In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 2001; 48: 398-406
79. Huang JX, Li FY, Xiao W, et al. Expression of thymidylate synthase and glutathione-stransferase π in patients with esophageal squamous cell carcinoma. World J Gastroenterol 2009; 15(34): 4316-21
80. Ji JH, Park SH, Lee J, et al. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis. Cancer Chemother Pharmacol 2013; 72(1): 223-30
81. Sartorius UA, Krammer PH. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 2002; 97: 584-592
82. Sun Z, Chen J, Aakre J, et al. Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients. Ann Oncol 2010; 21(10): 2011-6
83. Gourdier I, Del Rio M, Pau B, et al. Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma. FEBS Letters 2002; 529: 232-236
84. Elucidating side effects of antineoplastic agent. Science Daily.
85. Retrieved 7 May 2013 http://www.sciencedaily.com/releases/2010/10/101005141117.htm
86. Windsor RE, Strauss SJ, Kallis C, et al. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: A pilot study. Cancer 2012; 118 (7): 1856-67
87. Pieck AC, Drescher A, Wiesmann KG, et al. Oxaliplatin-DNA adduct formation in white blood cells of cancer patients. Br J Cancer 2008; 98: 1959-65
88. Veal GJ, Dias C, Price L, et al. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy. Clin Cancer Res 2001; 7: 2205-12.
89. Koutras AK, Makatsoris T, Paliogianni F, et al. Oxaliplatin induced acute-onset thrombocytopenia, hemorrhage and hemolysis. Oncology 2004; 67: 179-82
90. Carneiro BA, Kaminer L, Eldibany M, et al. Oxaliplatin-related acute myelogenous leukemia. Oncologist 2006; 11: 261-2
91. Argyriou AA, Polychronopoulos P, Iconomou G, et al. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 2008; 34: 368-77
92. Grolleau F, Gamelin L, Boisdron-Celle M, et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001; 85: 2293-7
93. Maindrault-Goebel F, Louvet C, Andre T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (folfox6). Eur J Cancer 1999; 35: 1338-42
94. Cavaletti G, Tredici G, Petruccioli MG, et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 2001; 37: 2457-63
95. Zafar S, Marcello J, Wheeler J, et al. Treatment-related toxicity and supportive care in metastatic colorectal cancer. J Support Oncol 2010; 8: 15-20
96. Apetoh L, Ghiringhelli F, Tesniere A, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007; 220: 47-59
97. Reynolds NA, Wagstaff AJ. Cetuximab: In the treatment of metastatic colorectal cancer. Drugs 2004; 64: 109-18
98. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45
99. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92
100. Nahta R, Hortobagyi GN, Esteva FJ. Growth factor receptors in breast cancer: Potential for therapeutic intervention. Oncologist 2003; 8: 5-17
101. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42
102. Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005; 128: 270-9
103. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug resistant cancer. Cancer Res 2000; 60: 1878-86
104. Huber PE, Bischof M, Jenne J, et al. Trimodal cancer treatment: Beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 2005; 65: 3643-55
105. ftp://ftp.cordis.europa.eu/pub/lifescihealth/docs/cancer-web-081117-en.pdf 30/05/2014